Genscript Biotech (HK:1548) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Genscript Biotech’s associate, Legend Biotech, is making strides in the treatment of multiple myeloma, providing promising data from the Phase 3 CARTITUDE-4 trial. Their CARVYKTI therapy, which targets BCMA, has been approved by both the FDA and European Commission, and is expanding its reach globally. This development highlights potential growth opportunities for investors in the biopharmaceutical sector.
For further insights into HK:1548 stock, check out TipRanks’ Stock Analysis page.
